Berbamine

Research use only, not for human use.

Berbamine and its derivatives are promising agents to suppress liver cancer growth by targeting CAMKII.

Berbamine has high binding affinity toward the (GGA);G-quadruplex. Berbamine and its derivatives are promising agents to suppress liver cancer growth by targeting CAMKII. Berbamine may be the first ATP-competitive inhibitor of CaMKII γ, could be as a new type of molecular targeted agent through inhibition of the CaMKII γ activity for treatment of leukemia. 4. Berbamine can enhance the antitumor activity of gemcitabine by inhibiting cell growth and inducing apoptosis, possibly through the regulation of the expression of apoptosis-related proteins and the activation of TGF-β/Smad signaling pathway. Berbamine confers cardioprotection against I/R injury by attenuating [Ca(2+)inf(i) overloading and preventing calpain activation through the activation of the PI3K-Akt-GSK3β pathway and, subsequently, opening of the mitoK(ATP) channel.

Cell Viability Assay Cell Line:KM3 cell Concentration:1?32 μg/mL Incubation Time:24, 48, or 72 h Result:Inhibited the growth of KM3 cells in a dose- and time-dependent manner.Apoptosis Analysis Cell Line:KM3 cell Concentration:4 μg/mLIncubation Time:6, 12, or 24 h Result:Induced apoptosis in a time-dependent manner treated at 8 μg/mL.Western Blot Analysis Cell Line:KM3 cell Concentration:8 μg/mL Incubation Time:0, 6, 12, or 24 h Result:Inhibited p65 nuclear translocation and expression of IKKα.

Animal Model:Huh7 xenograft NOD/SCID mice modelDosage:100mg/kg Administration:Oral gavage (p.o.), twice a day for 5 consecutive days Result:Suppressed tumor growth and reduced tumor weight by 70%.

——

Membrane Transporter/Ion Channel

TRP/TRPV Channel

CAMKIIγ

Cancer

——

478-61-5

608.73

C37H40N2O6

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (164.28 mM)

CN1CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)O)OC

——

(-20℃)

With Ice Pack

≥ 2 years